Table 2

Correlation between clinicopathological factors and PD-L1 expression in tumour cells or PD-1 expression in TILs

No. of patients (%)pNo. of patients (%)p
PD-L1 expression (n=166)PD-1 expression (n=164)
PositiveNegativePositiveNegative
Age (years)≤50
>50
25 (43)
37 (35)
33 (57)
70 (65)
 0.2815 (27)
25 (24)
41 (57)
83 (65)
 0.61
T1/2
3/4
53 (61)
39 (49)
34 (39)
40 (51)
 0.1354 (62)
40 (52)
33 (38)
37 (48)
 0.19
N0
≥1
47 (55)
45 (56)
39 (45)
35 (44)
 0.8449 (56)
45 (58)
38 (44)
32 (42)
 0.78
StageII
III
40 (40)
22 (34)
61 (60)
42 (66)
 0.1826 (25)
14 (23)
76 (75)
48 (77)
 0.21
Grade1 or 2
3
15 (28)
47 (42)
39 (72)
64 (58)
<0.0001 9 (17)
31 (28)
43 (83)
81 (72)
<0.0001
SubtypeTNBC
HR−/HER2+
HR+/HER2−
40 (49)
13 (33)
 9 (21)
41 (51)
27 (67)
35 (79)
<0.000126 (32)
 8 (20)
 6 (14)
56 (51)
32 (67)
36 (79)
<0.0001
pCRYes
No
33 (100)
59 (44)
 0 (0)
74 (56)
<0.000134 (100)
60 (46)
 0 (0)
70 (54)
<0.0001
TILHigh
Low
66 (76)
26 (33)
21 (24)
53 (67)
<0.000167 (78)
27 (35)
19 (22)
51 (65)
<0.0001
p53Positive
Negative
58 (67)
34 (43)
29 (33)
45 (57)
 0.007459 (70)
35 (44)
25 (30)
45 (56)
 0.002
ApoptosisScore 0, 1
Score 2
69 (54)
23 (59)
58 (46)
16 (41)
 0.6171 (56)
23 (61)
55 (44)
15 (39)
 0.65
  • HER2, human epidermal growth factor receptor 2; HR, hormone receptors; pCR, pathological complete response; PD-1, programmed cell death-1; PD-L1,  programmed cell death-ligand 1; TIL, tumour-infiltrating tumour cells; TNBC, triple-negative breast cancer.